1. Home
  2. /
  3. What is CAR T-cell...

What is CAR T-cell treatment?

In this section, you can find information about CAR T-cell therapy and its phases, alongside videos explaining different aspects of CAR T-cell treatment.

CAR T-cell therapy explained

 

 

CAR T-cell therapy is a novel form of immunotherapy to treat cancer using a patient’s own T-cells which are collected via leukapheresis or T-cells from a donor. In Europe, patients can be treated with CAR T-cell therapy as part of standard of care or by participating in a clinical trial.

 

Animation from Mofitt Cancer Center to explain CAR T-cell therapy. 

For more from Mofitt Cancer Center, click here.

Animation from the Children’s Hospital of Philadelphia. For more from the hospital, click here.

Currently, only CAR T-cell therapies using patients’ own T-cells are available as standard of care to treat hematologic cancers in Europe (i.e. not as part of a clinical trial). Although often only a single infusion with CAR T-cells is needed, the treatment trajectory is intensive and consists of several treatment phases. You can read more about the phases here.

CAR T-cell therapy phases

 

 

CAR T-cell therapy consists of multiple phases, starting with an initial screening phase and ending with continued follow-ups upon going through infusion.

On this page, you can learn more about the different phases and browse through resources from various sources selected by the T2EVOLVE consortium.

 

Infographic from the Mayo Clinic CAR-T Cell Therapy Program.

For more from the Mayo Clinic, see here.

Explainer videos produced by T2EVOLVE

How to identify reliable information on CAR T-cell therapy using the internet

This explainer video for patients shares basic information about CAR T-cell therapy and how to identify reliable information online.

T2EVOLVE wants to thank all the members of the Working Group of Patients and Caregivers (WGPC), and the patient advocacy groups Acute Leukemia Advocate Network (ALAN), Myeloma Patients Europe (MPE) and Lymphoma Coalition, for their essential contribution to the development of this video.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945393. This Joint Undertaking receives support from the European Union´s Horizon 2020 research and innovation program and EFPIA.

                   

 

Additional resources

The CAR T-CELL THERAPY/CLINICAL TRIAL JOURNEY: A Guide for Patients and Carers

The NA-ATTC is pleased to offer The CAR T-Cell Therapy Clinical Trial Journey – A Guide for Patients and Carers in partnership with Autolus Therapeutics. This Guide is intended for people who are either considering enrolling in or are already enrolled in a CAR T-cell therapy clinical trial. It contains information for both patients and those who care for them (92 pages).

Infographic on CAR T Cell Therapy Treatment Experience

Infographic from Bristol Myers Squibb.

Cell therapy treatment experience fact sheet (1 page).

Yourcartguide.co.uk

Information and advice on CAR T Cell Therapy by Gilead, helping patients through CAR T Cell treatment.

Webinar | Doctor and patients' perspective on myeloma CAR-T

Recording of webinar organised by Myeloma Patients Europe (MPE) on 14 February 2023.

This webinar includes the participation of Prof. Dr. Michel Delforge, Professor of Medicine and Clinical Head of Haematology at the University Hospital Leuven, Belgium, and two myeloma patients who have received CAR-T treatment: Tamra Fine, from the Netherlands, and William Kenneth Casler, from France.

The CAR T-Cell Therapy Clinical Journey Guide

This glossary from the Advanced Therapy Treatment Centres (ATTC) allows patients to look up terms related to CAR T.

CAR T cell mechanism of action explainer video

MD Anderson Cancer Center

This short video from the MD Anderson Cancer Center in Texas, USA, explains CAR T cell mechanism of action.

ALAN / Lymphoma Coalition Webinar: CAR-T cell therapies and what it means for patients

Full-length webinar by the ALAN / Lymphoma coalition (57 mins).

Share This